Integrated Advisors Network LLC Sells 27,540 Shares of Insulet Co. (NASDAQ:PODD)

Integrated Advisors Network LLC reduced its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 41.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,229 shares of the medical instruments supplier's stock after selling 27,540 shares during the quarter. Integrated Advisors Network LLC owned approximately 0.05% of Insulet worth $10,039,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Baillie Gifford & Co. increased its position in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after buying an additional 79,982 shares during the last quarter. Geode Capital Management LLC increased its position in Insulet by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after buying an additional 40,566 shares during the last quarter. Norges Bank purchased a new stake in Insulet in the fourth quarter worth $248,806,000. Artisan Partners Limited Partnership increased its position in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Northern Trust Corp increased its position in Insulet by 20.5% in the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after buying an additional 125,710 shares during the last quarter.

Insulet Price Performance

Insulet stock traded up $1.01 during midday trading on Friday, hitting $304.63. 670,638 shares of the company's stock were exchanged, compared to its average volume of 711,741. Insulet Co. has a 52-week low of $173.00 and a 52-week high of $329.33. The stock has a 50-day moving average price of $287.15 and a two-hundred day moving average price of $275.01. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market cap of $21.44 billion, a P/E ratio of 52.61, a PEG ratio of 3.62 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same period in the previous year, the business earned $0.73 earnings per share. The firm's revenue was up 28.8% on a year-over-year basis. On average, equities research analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PODD shares. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price for the company in a research report on Tuesday, May 13th. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price for the company. Piper Sandler raised their target price on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Stifel Nicolaus raised their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $318.41.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.